Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

1. Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.Antimicrobial agents and chemotherapy · 2013
   Trial
2. Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients.Antimicrobial agents and chemotherapy · 2010
   Trial
3. Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem cell transplant patients.Antimicrobial agents and chemotherapy · 2009
   Trial
4. Polyene Antibiotics Physical Chemistry and Their Effect on Lipid Membranes; Impacting Biological Processes and Medical Applications.Membranes · 2022
   Review
5. Extrapolating Antifungal Animal Data to Humans - Is it reliable?Current fungal infection reports · 2020
   Article
6. Increased Efficacy of Oral Fixed-Dose Combination of Amphotericin B and AHCCPharmaceutics · 2019
   Article
7. Extended Dosing Regimens for Fungal Prophylaxis.Clinical microbiology reviews · 2019
   Review
8. Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019
   Review
9. Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.Drugs · 2016
   Review
10. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection.Proceedings of the National Academy of Sciences of the United States of America · 2014
    Article
11. Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates.Antimicrobial agents and chemotherapy · 2013
    Article
12. Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis.Antimicrobial agents and chemotherapy · 2013
    Article
13. Micafungin in the treatment of invasive candidiasis and invasive aspergillosis.Infection and drug resistance · 2008
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as